home / stock / inzy / inzy quote
Last: | $4.23 |
---|---|
Change Percent: | -3.86% |
Open: | $4.39 |
Close: | $4.40 |
High: | $4.4892 |
Low: | $4.21 |
Volume: | 15,424 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.23 | $4.39 | $4.4 | $4.4892 | $4.21 | 15,424 | 04-25-2024 |
$4.4 | $4.4 | $4.4 | $4.49 | $4.3506 | 478,912 | 04-24-2024 |
$4.4 | $4.43 | $4.4 | $4.62 | $4.4 | 742,565 | 04-23-2024 |
$4.39 | $4.57 | $4.39 | $4.57 | $4.39 | 813,172 | 04-22-2024 |
$4.51 | $4.54 | $4.51 | $4.63 | $4.38 | 591,071 | 04-19-2024 |
$4.58 | $4.64 | $4.58 | $4.82 | $4.57 | 561,269 | 04-18-2024 |
$4.65 | $4.92 | $4.65 | $4.98 | $4.62 | 408,256 | 04-17-2024 |
$4.85 | $4.67 | $4.85 | $4.985 | $4.6 | 702,219 | 04-16-2024 |
$4.71 | $5.11 | $4.71 | $5.11 | $4.67 | 740,166 | 04-15-2024 |
$5.14 | $5.19 | $5.14 | $5.21 | $4.885 | 820,969 | 04-12-2024 |
$5.22 | $5.33 | $5.22 | $5.49 | $5.15 | 728,757 | 04-11-2024 |
$5.24 | $5.25 | $5.24 | $5.305 | $5.095 | 1,283,444 | 04-10-2024 |
$5.48 | $5.6 | $5.48 | $5.7 | $4.88 | 1,747,492 | 04-09-2024 |
$5.87 | $6.5 | $5.87 | $7.01 | $5.755 | 1,845,437 | 04-08-2024 |
$6.41 | $6.39 | $6.41 | $6.61 | $6.24 | 752,551 | 04-05-2024 |
$6.49 | $7.25 | $6.49 | $7.31 | $6.44 | 1,124,404 | 04-04-2024 |
$7.17 | $7.05 | $7.17 | $7.21 | $6.85 | 815,355 | 04-03-2024 |
$6.93 | $7.13 | $6.93 | $7.305 | $6.84 | 712,546 | 04-02-2024 |
$7.31 | $7.66 | $7.31 | $7.795 | $6.96 | 935,011 | 04-01-2024 |
$7.66 | $7.53 | $7.66 | $7.725 | $7.275 | 1,260,446 | 03-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
Inozyme Pharma Inc. Company Name:
INZY Stock Symbol:
NASDAQ Market:
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said...
2024-04-09 08:00:07 ET Edward White from H.C. Wainwright issued a price target of $14.00 for INZY on 2024-04-09 06:36:00. The adjusted price target was set to $14.00. At the time of the announcement, INZY was trading at $5.87. INZY currently trades -24.97% versus its 52 ...
- Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) - - Natural history study highlights stroke as common feature among patients with early-onset ABCC6 Deficiency - ...